Green Thumb Industries Shows Strong Upside Potential Despite Market Pullback

Key Points

• Unlike many cannabis companies, Green Thumb operates profitably and is driven by a growth catalyst that is independent of broader legalization efforts.

• Additional strengths further reinforce its position as a leading cannabis play.

• Consequently, it remains an attractive option for investors optimistic about the cannabis market.

Green Thumb Industries (OTC: GTBIF) has experienced only a modest decline since its brief rally in April among marijuana stocks. Although the shares have remained relatively stable, this does not necessarily indicate that the stock is fairly valued at current price levels.

In fact, taking into account its solid operating results and other fundamentals, Green Thumb appears to be a compelling choice for investors who are confident in the prospect of clearer U.S. federal cannabis regulations and expanded commercial sales.

Image source: Getty Images.

Why Green Thumb stands out

Although many prominent cannabis stocks originate in Canada, Green Thumb is headquartered in Chicago and is a prominent multistate operator (MSO). MSOs own and manage marijuana businesses licensed at the state level. Unlike Canada‑based firms, which remain constrained from entering the U.S. market and struggle to achieve profitability, companies like Green Thumb have consistently delivered profits.

For example, Green Thumb has been GAAP‑profitable since 2020. Coupled with a proven profitability record, the company possesses a catalyst that could markedly boost earnings in the near term. Earlier this year, it renegotiated its licensing agreement with Rhythm (NASDAQ: RYM), in which it holds a 50% stake. Under the new terms, Green Thumb pays a fixed licensing fee for Rhythm’s trademarks instead of a percentage of revenue, thereby increasing operating leverage. This arrangement positions the company for earnings growth that could potentially double its share price from current levels.

Additional catalysts to consider

Additional factors that could further accelerate its share price include the receipt of a conditional license that enables Green Thumb to operate in Texas’s upcoming medical‑cannabis market, as well as a continued aggressive share‑repurchase program that recently increased its buyback ceiling by $100 million, representing roughly 6% of its outstanding shares.

Although the stock currently trades at a forward‑earnings multiple of about 38.8, the convergence of these bullish catalysts suggests that analysts may be underestimating the company’s profit potential. For investors seeking exposure to the marijuana‑legalization narrative, MSOs such as Green Thumb continue to present a compelling choice.

Investment Outlook for Green Thumb Industries

Prospective investors should evaluate the following factors before acquiring shares of Green Thumb Industries.

Overall, Green Thumb’s combination of consistent profitability, strategic licensing adjustments, and expanding market opportunities positions it as a noteworthy player for investors watching the U.S. cannabis landscape.

Source link